Project Grant HT94252410860

This Project Grant award, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), aims to investigate mechanisms of resistance to KRAS G12C inhibitors in SMARCA4-mutant lung cancer. The $267,527 award will fund research at The University of Texas M.D. Anderson Cancer Center to: 1) Examine the molecular basis for reduced responsiveness to KRAS G12C inhibitors in SMARCA4-mutant lung cancer models, 2) Evaluate the potential of SMARCA2-targeting...

This Project Grant award of $631,156 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393) supports research to uncover the core mechanisms driving lineage plasticity (LP) in EGFR-mutant lung adenocarcinoma (LUAD). The research aims to systematically define the epigenetic, transcriptional, and signaling alterations that facilitate the transformation of LUAD to the more aggressive small cell lung cancer (SCLC) subtype, a lethal mechanism...

This Project Grant award of $435,827, provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research at New York University School of Medicine to investigate methods for enhancing the effectiveness of KRAS inhibitor cancer therapies. The research aims to identify synthetic lethal genetic interactions that could be leveraged to improve outcomes for patients with KRAS-mutated cancers, which are common in lung, colorectal, and pancreatic...

This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $703,410.00 to New York University School of Medicine to conduct research on the adeno-to-squamous transition in non-small cell lung cancer. The research aims to identify chromatin regulators that drive this cellular adaptation, which enables resistance to targeted KRAS inhibitor therapy. The award began on January 16, 2025 and is scheduled to run through December 31, 2029....

This Project Grant award from the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) supports research to investigate how inhibition of the ABL kinase enzyme can sensitize small cell lung cancer (SCLC) to metabolic disruptions, leading to cell death. The $165,196 award to Duke University was made on December 1, 2024 and is scheduled for completion by May 31, 2026. The researchers have performed a CRISPR/Cas9 screen to identify combination therapy targets that synergize with the ABL...

The National Cancer Institute (NCI) awarded a $730,400 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the Sloan-Kettering Institute for Cancer Research in New York. The goal of this 5-year project is to determine how specific metabolic configurations in lung adenocarcinoma (LUAD) cancer cells support the emergence and maintenance of treatment-resistant cell states. The research team will manipulate components of the tricarboxylic acid (TCA) cycle in mouse and...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $458,051 to Temple University to conduct research aimed at understanding and targeting vulnerabilities in small cell lung cancer (SCLC). The key products and services to be delivered under this 4-year award include: Investigating whether low levels of the nuclear structural protein LMNA contribute to the high levels of replication stress observed in SCLC cells, and whether this...

This $557,418 federal Project Grant was awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on March 17, 2025 to The Trustees of Columbia University in the City of New York for the project "Targeting SMARCA2 in SMARCA4-Deficient Lung Cancers In Vivo". The project aims to mechanistically evaluate SMARCA2 degradation as a therapeutic approach for treating SMARCA4-deficient lung adenocarcinomas, which account for ~20,000 new lung cancer cases annually in the...

This Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports research to discover new therapeutic strategies for small cell lung cancer (SCLC). The $191,675 award to The University of Texas Southwestern Medical Center will investigate the role of Jumonji lysine demethylases (Jumonji KDMs) as potential druggable targets in SCLC, including for tumors that have developed resistance to standard chemotherapy. The...

This federal Project Grant award of $166,800.00 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research at Pennsylvania State University's Milton S. Hershey Medical Center to investigate a novel combination therapy approach for an aggressive subtype of lung adenocarcinoma. The research aims to characterize how the loss of the MTSS1 protein impacts the tumor immune microenvironment in SMARCA4-mutant lung adenocarcinoma, and evaluate the...